Interest in the subjective well-being (SW) of psychiatric patients has significantly increased over recent years. While, for a long time, symptom reduction alone was the most essential outcome parameter, more detailed success criteria are now being implemented, approximately 50 years after the introduction of neuroleptic treatment. Considering the extensive use of typical neuroleptics over the last decades, surprisingly little evaluation of patients’ subjective complaints while being medicated has been performed. In terms of tolerability, investigators focused on motor symptoms when looking at drug-induced complaints and reasons for noncompliance. With the development of atypical antipsychotics, treatment goals became more ambitious, the patient’s perspective was considered more, and complaints such as affective blunting and cognitive slowing, as well as volition and loss of spontaneity, received greater interest. These emotional restrictions have been described as “neuroleptic dysphoria,” “pharmacogenetic depression,” “akinetic depression,” “neuroleptic depression,” and “neuroleptic-induced anhedonia.”

The increased interest in subjective well-being was not only due to a conceptual shift in therapeutic outcome criteria:

• Studies on subjective well-being disproved the former belief that schizophrenic patients are not able to reliably assess their SW. The majority of schizophrenic patients, if not acutely psychotic or suffering from severe cognitive impairment, are able to complete self-rating scales in a consistent and reliable manner.

Author affiliations: Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Address for correspondence: Prof Dr Dieter Naber, Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany (e-mail: naber@uke.uni-hamburg.de)
The impact of antipsychotic drugs on subjective well-being (SW), together with the quality of the doctor–patient relationship, is one of the two agreed major determinants for medication compliance.\textsuperscript{18-23} Despite significant advances in the pharmacotherapy of schizophrenia, noncompliance, particularly in long-term treatment, remains a major problem. Rates of noncompliance vary because of inconsistent definitions and heterogeneous samples; studies show that 25\% to 70\% of all schizophrenic patients are noncompliant.\textsuperscript{18-20,24} Although compliance somewhat improved under treatment with atypical antipsychotics, adherence rates at 6 and 12 months were only moderately higher compared with patients receiving typical agents.\textsuperscript{25} Since noncompliance is one of the most important risk factors for relapse,\textsuperscript{18} enhanced medication adherence is an urgent task. Due to the advances in psychopharmacological as well as in psychosocial/psychoeducational treatments, chances for better long-term prognosis have been improved, and remission has become a major goal in the treatment of schizophrenia. Most recently, the Remission in Schizophrenia Working Group published a consensus statement on definition criteria and time thresholds of remission in schizophrenia.\textsuperscript{30} The European Schizophrenia Outpatient Health Outcomes (SOHO) study\textsuperscript{26-29} was one of the first to assess these criteria, including a self-rating, in a large sample of patients.

**Measurement of subjective well-being**

Subjective well-being is a major component of quality of life,\textsuperscript{31} influenced by the pharmacological and/or psychosocial treatment as well as by the illness itself. A multitude of components, for example patients’ attitudes toward medication or other nonpharmacological factors, possibly interfere when their subjective experience of neuroleptic drugs is investigated.

Naber suggested a model consisting of five dimensions of SW: emotional regulation, self-control, mental functioning, social integration, and physical functioning.\textsuperscript{15} Lambert et al\textsuperscript{14} combined this concept with six influencing factors: psychopathology and symptomatic improvement, physical side effects and associated distress, attitudes toward pharmacological treatment and insight, psychosocial factors, phase, and severity of illness. One major impetus for this research was the sometimes marked subjective improvement, when patients were switched from typical antipsychotics to clozapine.\textsuperscript{32} Similarly to the first trial, quality of life was an outcome criterion to assess the improvement by clozapine.\textsuperscript{33} The Subjective Well-being under Neuroleptic treatment (SWN) is a self-rating Likert scale with 20 items (10 positive, 10 negative) and good psychometric properties.\textsuperscript{18,34} Recently, an algorithm has been developed to exclude patients who are unable to understand the items or to reliably fill out the scale, based on analyzing mean differences between negative and positive items for the individual subscores (S. Moritz, unpublished data). Starting with the pioneer work of the Drug Attitude Inventory of Hogan et al,\textsuperscript{35} there now exist, together with the SWN, several self-rating instruments to investigate the patients’ perspective of antipsychotic treatment.\textsuperscript{32}

**Psychopathology and subjective well-being**

The relationship between psychopathology, as shown with the Positive and Negative Syndrome Scale (PANSS), and the subjective well-being, as measured with the SWN, was investigated in several trials.\textsuperscript{15,35-37} The total score, as well as the subscales were only moderately correlated with the PANSS scores ($r$=-0.1 to –0.5) with stronger relationships to the negative and global score than to the positive score. The highest correlations ($r$=-0.4 to –0.5) were related to the severity of depression and anxiety. Regarding the impact of side effects, Lambert et al\textsuperscript{38} found, in a study in 213 patients treated with typical neuroleptics, that sexual dysfunctions and extrapyramidal and psychic side effects were rated as subjectively more distressing than vegetative side effects and sedation.

In a study by de Haan et al\textsuperscript{39} it was shown that dosage of medication leading to dopamine ($D_2$) receptor blockade should be carefully evaluated, since it is most likely responsible for neuroleptic dysphoria, even in the absence of motor side effects.\textsuperscript{40,41} The relationship between SWN and striatal $D_2$ receptor occupancy was investigated in 22 schizophrenic patients, clinically stable under either 14.7 mg of olanzapine or 4.1 mg of risperidone. It was demonstrated that in the absence of extrapyramidal symptoms, higher striatal $D_2$-receptor...
occupancy as measured by single photon-emission computed tomography (SPECT) was related to reduced SWN, negative symptoms, and depression ($P<0.01$).

**Atypical antipsychotics, subjective well-being, and compliance**

Naber$^{15}$ investigated the subjective perception of neuroleptic treatment with the SWN and found it to be significantly related to noncompliance. Forty-eight patients rated their SWN prior to discharge from inpatient treatment. Six months later, 14 patients were noncompliant. Compared with 34 patients who remained compliant, their SWN at discharge was significantly lower ($P<0.05$). However, the psychiatrists did not see a difference between future compliant or noncompliant patients; the PANSS scores did not differentiate between both groups.

In another patient population, it was shown that the SWN of 28 patients treated with the atypical antipsychotic clozapine because of therapy resistance or motor side effects was, despite negative selection, significantly better than the SWN score of 38 patients under classical neuroleptics ($P=0.03$). In a later study, olanzapine and clozapine were compared in a double-blind, controlled trial in 114 patients, over a 26-week period.$^{37}$ Regarding SWN, the total score—as well as all subscores, excluding mental functioning—showed a significant relationship between low SWN and noncompliance ($P<0.005 – P<0.01$). Again, this study showed that the improvement of SWN and of PANSS are not strongly related ($r=-0.3$ to -0.4).

The SOHO study also found a relevant relationship between subjective well-being and compliance. It is a 3-year investigation of the health outcomes associated with antipsychotic treatment in Europe.$^{26-29}$ Data were collected in a prospective, nonrandomized observational study of 10 972 patients with schizophrenia, recruited in 10 European countries between January and December 2001. In the German study population with 2960 patients, SWN was used to assess the patients’ perspective. At baseline, patients and physicians categorized compliance as “almost always compliant,” “partly compliant,” or “almost never compliant.” The relationship between changes in compliance (improvement $n=225$, no change $n=1366$, worsening $n=78$) and clinical variables were assessed by factor analysis. This revealed the strongest correlations for SWN ($r^2=0.866$), followed by symptoms ($r^2=0.772$) and side effects ($r^2=0.480$) (Karow et al, unpublished data). SW seems to be of potent influence on adherence during maintenance treatment, but not in the acute phase, as Mutsatsa et al$^{43}$ did not find a significant relationship between SWN and early medication adherence in 101 first-episode patients.

Numerous studies show the advantages of atypical versus typical antipsychotics, and these advantages are most prominent from the patients’ perspectives: Atypical antipsychotics improve subjective quality of life more than typical antipsychotics,$^{44,45}$ subjective response is significantly better under atypical compared with typical drugs,$^{46}$ and, not surprisingly, switching from a typical to atypical antipsychotic is associated with a marked subjective improvement.$^{47,48}$

**Subjective well-being as a remission criterion in the SOHO study**

In the SOHO study, SWN was used as an important single component of the complete remission criterion, according to the new consensus statement on criteria and the time frame of remission in schizophrenia published by the Remission in Schizophrenia Working Group.$^{38}$ In contrast to previous definitions, the consensus included the incorporation of subjective rating next to sustained symptomatic (ie, positive, negative, and cognitive symptoms) as well as functional remission (ie, activities of daily living, employment).$^{49-57}$

Remission criteria and predictor variables were assessed at baseline, at 3, 6, 12, 18, and 24 months with standardized scales. Complete remission was defined as patients fulfilling all criteria for (i) symptomatic, (ii) functional, and (iii) subjective well-being over a period of at least 6 months (ie, at the 18-month and 24-month visits). Symptomatic remission was defined as receiving a Clinical Global Impressions Scale (CGI)-Schizophrenia score$^{36}$ of no worse than “mild” ($\leq3$) in assessments of overall severity, positive, and cognitive subscores and a score of no worse than “moderate” ($\leq4$) in the negative subscore. Functional remission was defined as a positive occupational/vocational status, ie, paid or unpaid, full- or part-time employment, being an active student or head of a household with an employed partner, and independent living, ie, living alone, living with a partner, living with peers. Subjective well-being was met if a SWN total score of $\geq80$ points was achieved.

Predictor variables were (i) baseline predictors, (ii) early course of treatment predictors defined as fulfilled remis-
sion criteria at 3 months, and (iii) course of treatment predictors defined as variables assessed continuously throughout the complete 24-month period. The baseline predictors were (i) age, gender, and duration of illness, (ii) symptomatic status assessed with the expanded version of the CGI-Schizophrenia including an overall severity of illness score and 4 subscores for the severity of positive, negative, cognitive, and depressive syndromes, (iii) functional variables included the occupational/vocational status and independent living assessed in yes/no categories, (iv) subjective well-being assessed with the SWN. The early course of treatment predictors were early symptomatic, functional, and subjective well-being remission at 3 months. The course of treatment predictors were compliance with antipsychotic medication, (non)compliance was defined as missing ≥50% of medication over at least 4 weeks) and comorbid substance use disorder (SUD) according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, categorized into (i) no SUD; (ii) remitted SUD (remission during follow-up with SUD at baseline); and (iii) persistent SUD. Lambert et al (unpublished data) found that 50% of the patients achieved symptomatic remission and about 40% subjective well-being remission, whereas only one third sustained functional remission. Including symptomatic and functional criteria, 19% achieved complete remission in the SOHO study; following the consensus statement regarding the relevance of side effects or success of antipsychotic treatment. Subjective well-being is at least a valuable addition to objective (?) psychopathology, and should become an integral part of shared decision-making. A better consideration of the patients’ perspective can improve therapeutic alliance, medication adherence, and, finally, the long-term prognosis.

**Conclusion**

For a long period, many psychiatrists believed that they knew their patients well enough not to need additional self-ratings by the patients. However, numerous trials have revealed that both perspectives differ markedly regarding the relevance of side effects or success of antipsychotic treatment. Subjective well-being is at least a valuable addition to objective (?) psychopathology, and should become an integral part of shared decision-making. A better consideration of the patients’ perspective can improve therapeutic alliance, medication adherence, and, finally, the long-term prognosis.

**REFERENCES**

1. Van Putten T, May RP. Akinetic depression in schizophrenia. Arch Gen Psychiatry. 1978;35:1101-1107.
2. Liddle PF, Barnes TRE. The subjective experience of deficits in schizophrenia. Comp Psychiatry. 1988;29:157-164.
3. Jaeger J, Bitter I, Czobor P, Volavka J. The measurement of subjective experience in schizophrenia. Comp Psychiatry. 1990;31:216-226.
4. Selten JP, Sijben NES, Van den Bosch RJ, Omloo-Vissen J, Warmerdem H. The subjective experience of negative symptoms: a self rating scale. Compr Psychiatry. 1993;34:192-197.
5. Singh MM, Smith JM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst. 1976;37:191-196.
6. Hogan TP, Awad AG, Eastwood MR. A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminate validity. Psychol Med. 1983;13:177-183.
7. Windgassen K. Treatment with neuroleptics: the patient’s perspective. Acta Psychiatr Scand. 1992;86:405-410.
8. Lewander T. Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand. 1994;80(suppl):8-13.
9. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology. 2004;171:121-132.
10. Gerlach J, Larsen EB. Subjective experience and mental side effects of antipsychotic treatment. Acta Psychiatr Scand. 1999;99(suppl. 395):113-117.
11. Weiden PJ, Mann JJ, Dixon L, Haas G, Dechillo N, Frances AJ. Is neuroleptic dysphoria a healthy response? Compr Psychiatry. 1989;30:546-552.
12. Hellevoll JSE. Patients’ subjective experiences of antipsychotics: clinical relevance. CNS Drugs. 2002;16:457-471.
13. Voruganti LP, Awad AG. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Can J Psychiatry. 2004;49:285-289.
14. Lambert M, Graf Schimmelmann B, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs – concepts, measurement and clinical relevance. Pharmacopsychiatry. 2003;36:1-10.
15. Naber D. A self rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life and other clinical variables. Int Clin Psychopharmacol. 1995;10(suppl 3):133-138.
El proyecto MATRICS del NIMH para desarrollar agentes que mejoren la cognición en la esquizofrenia

El Instituto Nacional de Salud Mental de los Estados Unidos ha financiado una iniciativa para facilitar el desarrollo de psicofármacos para mejorar la neurocognición en pacientes con esquizofrenia. Esto se ha llevado a cabo mediante un proceso consensuado en que se han incluido representantes del mundo académico, de la industria farmacéutica y del gobierno. El grupo ha señalado los obstáculos para el desarrollo de fármacos, los que incluyen: (i) la falta de un instrumento bien aceptado para medir la neurocognición en los ensayos clínicos, (ii) la falta de consenso respecto al mejor o los mejores objetivos moleculares para el desarrollo de fármacos, (iii) la falta de consenso respecto al diseño de ensayos óptimos tanto para la medicación que mejore la cognición cuando se asocia a un antipsicótico como para un fármaco de amplio espectro que mejore la cognición y trate la psicosis y (iv) los procedimientos de las agencias reguladoras, como la FDA de los Estados Unidos, para aprobar y clasificar un nuevo fármaco.

Impact sur l’observance et la rémission du bien-être subjectif ressenti sous traitement neuroleptique.

Le point de vue du patient sur el traitement antipsychotique a été très négligé pendant une longue période. C’est seulement depuis ces 10 dernières années, avec le développement des antipsychotiques atypiques, que l’intérêt scientifique sur cette question s’est accru considérablement. De nombreuses études ont montré que la majorité des patients schizophrènes est capable de remplir une échelle d’auto-appréciation de façon intelligible et plusieurs échelles de ce type avec une cohérence interne suffisante et une bonne validité de construction ont été développées. Les effets du traitement antipsychothique sur la psychopathologie et sur le bien-être subjectif (BS) sont peu rapportés ; les points de vue du patient et de son psychiatre diffèrent sensiblement. Des recherches récentes montrent que le rapport BS/qualité de vie, plus amélioré par les antipsychotiques atypiques que typiques, influe beaucoup sur l’observance comme sur la probabilité de rémission. Les données suggèrent fortement que l’évaluation systématique du traitement antipsychotique par le patient est significative et nécessaire pour augmenter l’observance, le résultat fonctionnel et le pronostic à long terme.
Clinical research

31. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology. 2002;162:24-28.
32. Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatr Scand. 2005;111:81-83.
33. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Commun Psychiatry. 1990;41:892-897.
34. de Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology. 2002;162:24-28.
35. Hogan TP, Award AG, Eastwood R. A self report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
36. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79-88.
37. Naber D, Riedel M, Klinke A, et al. Randomized double blind comparison of olanzapine and clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005;111:106-115.
38. Lambert M, Conus P, Eide P, et al. Impact of present and past side effects on the attitude towards typical antipsychotic treatment. Eur Psychiatry. 2004;19:415-422.
39. de Haan L, Lavalaye J, Linszen D, et al. Subjective experiences and striatal dopamine D2 receptor occupancy in patients with recent onset schizophrenia treated with olanzapine or risperidone. Am J Psychiatry. 2000;157:1019-1020.
40. Voruganti LP, Award AG. Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatr Scand. 2005;(suppl 427):22-28.
41. Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour – review of data from preclinical research. Acta Psychiatr Scand. 2005;(suppl 427):14-21.
42. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit scale. Schizophr Bull. 1984;10:388-398.
43. Muttsatsu SH, Joyce EM, Hutton SB, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 2003;108:439-446.
44. Award AG, Voruganti LNP. New antipsychotics, compliance, quality of life, and subjective tolerability – are patients better off? Can J Psychiatry. 2004;49:297-302.
45. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs. 2004;18(suppl 2):1-13.
46. Ritsner M, Pereöroyzen G, Ilan H, Gibel A. Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice. A naturalistic comparative study. J Clin Psychopharmacol. 2002;24:245-254.
47. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43:135-145.
48. Voruganti L, Cortese L, Oyewumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002;57:201-208.
49. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50:369-376.
50. Eaton WW, Thara R, Federman E, et al. Remission and relapse in schizophrenia: the Madras longitudinal study. J Nerv Ment Dis. 1998;186:357-363.
51. Ho BC, Andreasen NC, Flaim M, et al. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry. 2000;157:808-815.
52. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:473-479.
53. Curtis CE, Calkins ME, Grove WM, et al. Saccadic disinhibition in patients with acute and remitted schizophrenia and their first-degree biological relatives. Am J Psychiatry. 2001;158:100-106.
54. Liberman RP, Kopelowicz A, Venture J, et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002;14:256-272.
55. Yen CF, Chen CS, Yeh ML, et al. Comparison of insight in patients with schizophrenia and bipolar disorder in remission. J Nerv Ment Dis. 2002;190:847-849.
56. Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2002;14:256-272.
57. Kane JM, Leucht S, Carpenter D. Expert Consensus Guidelines for Optimizing Pharmacologic Treatment of Psychotic Disorders. J Clin Psychiatry. 2003;64(suppl 12):5-19.
58. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptom present in schizophrenia. Acta Psychiatr Scand. 2003;(suppl 416):16-23.
59. Pantelis C, Lambert TJ. Managing patients with “treatment-resistant” schizophrenia. Med J Aust. 2003;178:62-67.
60. Lambert M, Conus P, Lubman DJ, et al. The impact of substance use disorders on clinical outcome in 668 patients with first-episode psychosis. Acta Psychiatr Scand. 2003;112:141-148.
61. Fitzgerald PB, De Castella ARA, Filia K, et al. A longitudinal study of patient- and observer-rated quality of life in schizophrenia. Psychiatry Res. 2003;119:55-62.